Is CBD legal in the United States?
Products containing Cannabidiol, also known as CBD, are either a hemp-based product or from a marijuana plant. CBD is a federally scheduled illegal drug, much like cannabis. Fifteen state statues allow for CBD products as compared to 23 states that allow medical marijuana. As of June 2015, these states are Alabama, Georgia, Florida, Iowa, Kentucky, Mississippi, Missouri, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Utah, Virginia, and Wisconsin.
Idaho and New York have weighed in on the CBD oil legality as well, but are not currently legal. The federal government has sent out warning letters to some CBD-producing cannabis companies because they are producing an unapproved new drugs that haven’t been approved by the Federal Drug Administration for the diagnosis, cure, mitigation, treatment, or prevention of any disease.
It’s important that any marijuana consumer do their own research to make informed decisions on the medical cannabis products they purchase. Some companies offering CBD products have alleged that their cannabis products have the ability to reduce symptoms associated with cancer, seizures, mental disorders such as depression, neurological disorders; anti- cancer cells, helps ease chemotherapy side effects, as well as an assortment of other ailments.
What is Epidiolex? A CBD Pharmaceutical.
CBD, a cannabinoid found in cannabis, has been showing more interest in medicine specifically helping children with seizures. CBD does not contain THC which is the pyscho active cannabinoid also found in marijuana. The treatment of CBD for the treatment of children with CBD is a highly debated topic. It has shown potential in treating severe forms of epilepsy. Some medical cannabis patients have found success with a mix of CBD high concentrate and a low concentrate of the psychoactive ingredient, THC. The FDA has authorized investigatory new drug program for the pharmaceutical, Epidiolex, which has been used to treat a rare form of childhood epilepsy known as Dravet syndrome. In order to change the current legislation, the Federal Drug Administration would have to rewrite the regulation.